KALA BIO(KALA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KALA KALA BIO

Not Yet Opened 12-22 16:00:00 EST

0.5866

-0.0357

-5.74%

盘后0.5801

-0.0065-1.11%

19:58 EST

High0.6440	Low0.5800	Vol990.97K
Open0.6180	D1 Closing0.6223	Amplitude10.28%
Mkt Cap6.29M	Tradable Cap6.29M	Total Shares10.73M
T/O605.91K	T/O Rate9.24%	Tradable Shares10.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KALA","market":"US","secType":"STK","nameCN":"KALA BIO","latestPrice":0.5866,"timestamp":1766437200000,"preClose":0.6223,"halted":0,"volume":990968,"hourTrading":{"tag":"盘后","latestPrice":0.5801,"preClose":0.5866,"latestTime":"19:58 EST","volume":100632,"amount":57598.6943,"timestamp":1766451513240},"delay":0,"floatShares":10729725,"shares":10729725,"eps":-5.825375,"marketStatus":"Not Yet Opened","change":-0.0357,"latestTime":"12-22 16:00:00 EST","open":0.618,"high":0.644,"low":0.58,"amount":605914.0550804,"amplitude":0.102844,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.825375,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1500523200000,"exchange":"NASDAQ","adjPreClose":0.6223,"preHourTrading":{"tag":"盘前","latestPrice":0.6015,"preClose":0.6223,"latestTime":"09:27 EST","volume":22848,"amount":13933.358140800001,"timestamp":1766413625096},"postHourTrading":{"tag":"盘后","latestPrice":0.5801,"preClose":0.5866,"latestTime":"19:58 EST","volume":100632,"amount":57598.6943,"timestamp":1766451513240},"volumeRatio":0.400169,"impliedVol":0.9132,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/KALA","defaultTab":"news","newsList":[{"id":"2589881278","title":"KALA BIO Raises $10 Million From Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2589881278","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589881278?lang=en_us&edition=fundamental","pubTime":"2025-12-06 03:56","pubTimestamp":1764964616,"startTime":"0","endTime":"0","summary":"KALA BIO  said Friday it has closed its registered direct offering of 10 million shares at $1.00 per share, raising about $10 million.Investors could also buy pre-funded warrants in lieu, the company said.KALA BIO said it plans to use the net proceeds to repay debt and for general corporate purposes.Shares of KALA BIO fell over 5% in recent trading.Price: 0.91, Change: -0.05, Percent Change: -5.29","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1169590202.USD","BK4139","BK4007","BIO","LU1169589451.USD","BK4121","BK4588","KALA","BK4585"],"gpt_icon":1},{"id":"2588835314","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:45 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588835314","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588835314?lang=en_us&edition=fundamental","pubTime":"2025-12-04 23:45","pubTimestamp":1764863138,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:45 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nAQN2LC3U7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2588835397","title":"KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2588835397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588835397?lang=en_us&edition=fundamental","pubTime":"2025-12-04 23:45","pubTimestamp":1764863114,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA3BHXGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KALA","BK4007"],"gpt_icon":0},{"id":"2588835393","title":"KALA BIO Inc - Purchase Price Set at $1.00 per Share in Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2588835393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588835393?lang=en_us&edition=fundamental","pubTime":"2025-12-04 23:45","pubTimestamp":1764863114,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA3BHXGB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","KALA"],"gpt_icon":0},{"id":"2588283536","title":"Press Release: KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2588283536","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588283536?lang=en_us&edition=fundamental","pubTime":"2025-12-04 23:45","pubTimestamp":1764863100,"startTime":"0","endTime":"0","summary":"ARLINGTON, Mass., Dec. 04, 2025  -- KALA BIO, Inc.  , today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock , at a purchase price of $1.00 per share  in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 5, 2025, subject to the satisfaction of customary closing conditions.KALA is a clinical-stage biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for rare and severe diseases of the eye. KALA's biologics-based investigational therapies utilize KALA's proprietary mesenchymal stem cell secretome  platform. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors. KPI-012 received Orphan Drug and Fast Track designations from ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","NQmain","BK4588","BIO","LU1169589451.USD","BK4121","BK4139","BK4585","KALA","BK4007"],"gpt_icon":0},{"id":"2588089900","title":"Why Did KALA BIO Shares Jump Over 22% After Hours?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588089900","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588089900?lang=en_us&edition=fundamental","pubTime":"2025-12-04 13:20","pubTimestamp":1764825600,"startTime":"0","endTime":"0","summary":"KALA BIO shares jumped over 22% after Oxford Finance acquired a 16.5% stake, amid recent leadership changes and continued year-to-date losses.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/Stock-Market-Analysis--Notebooks--Laptop.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/Stock-Market-Analysis--Notebooks--Laptop.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/12/49201364/why-did-kala-bio-shares-jump-over-22-after-hours","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/12/49201364/why-did-kala-bio-shares-jump-over-22-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","KALA","BK4588","BK4007","LU1169589451.USD","LU1169590202.USD","BK4121","BK4139","BIO"],"gpt_icon":0},{"id":"2588022991","title":"Kala Bio Inc. Files Initial Beneficial Ownership Statement Naming Oxford Finance LLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2588022991","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588022991?lang=en_us&edition=fundamental","pubTime":"2025-12-04 06:01","pubTimestamp":1764799294,"startTime":"0","endTime":"0","summary":"Kala Bio Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission, naming Oxford Finance LLC as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL25WPdp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALA","BK4007","BK4139"],"gpt_icon":0},{"id":"2588377769","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588377769","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588377769?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:32","pubTimestamp":1764613968,"startTime":"0","endTime":"0","summary":"Q32 Bio's  shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.Kala Bio  said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.Belite Bio  said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.Price: 4.40, Change: +2.21, Percent Change: +","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","KALA","AKBA","BK4139","BLTE","QTTB"],"gpt_icon":0},{"id":"2588724793","title":"KALA BIO Inc: Continuing to Evaluate and Redevelop Co's Product Candidates While Actively Exploring Strategic Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724793","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724793?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9Q9SXS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2588724244","title":"KALA BIO Inc - David E. Lazar Appointed as Kala's CEO and Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724244","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724244?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9Q9SXS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2588347722","title":"KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar","url":"https://stock-news.laohu8.com/highlight/detail?id=2588347722","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588347722?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196847/0/en/KALA-BIO-Enters-Into-6-Million-Securities-Purchase-Agreement-with-Investor-David-E-Lazar.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIO","BK4121","KALA","BK4588","BK4585","LU1169589451.USD","LU1169590202.USD","BK4007"],"gpt_icon":0},{"id":"2586267875","title":"Kala Bio Inc. Files Initial Statement of Beneficial Ownership for CEO and Director David E. Lazar","url":"https://stock-news.laohu8.com/highlight/detail?id=2586267875","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586267875?lang=en_us&edition=fundamental","pubTime":"2025-11-27 03:51","pubTimestamp":1764186680,"startTime":"0","endTime":"0","summary":"Kala Bio Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists David E. Lazar as the beneficial owner, serving as both Director and Chief Executive Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDLWBL9P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2586238268","title":"What Sparked KALA BIO's Nearly 38% Surge Overnight?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586238268","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586238268?lang=en_us&edition=fundamental","pubTime":"2025-11-26 13:34","pubTimestamp":1764135240,"startTime":"0","endTime":"0","summary":"KALA BIO shares surged over 37% in after-hours trading following a private placement, loan settlement, and leadership changes.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/26/Stock-Market-Growth-Vector-With-Green-Ca.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/26/Stock-Market-Growth-Vector-With-Green-Ca.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/equities/25/11/49076865/what-sparked-kala-bios-nearly-38-surge-overnight","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/49076865/what-sparked-kala-bios-nearly-38-surge-overnight","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4588","BK4585","LU1169589451.USD","BIO","KALA","LU1169590202.USD","BK4121","BK4007","BK4139"],"gpt_icon":0},{"id":"2586984404","title":"BRIEF-Kala Bio Inc - On Nov 21, Board Terminated Without Cause The Employment Of Mary Reumuth, Company's Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586984404","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586984404?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:18","pubTimestamp":1764109135,"startTime":"0","endTime":"0","summary":"BRIEF-Kala Bio Inc - On Nov 21, Board Terminated Without Cause The Employment Of Mary Reumuth, Company's Chief Financial OfficerNov 25  - KALA BIO Inc KALA.O:KALA BIO INC - ON NOV 21, BOARD TERMINATED WITHOUT CAUSE THE EMPLOYMENT OF MARY REUMUTH, COMPANY'S CHIEF FINANCIAL OFFICERKALA BIO INC - ON NOV 21, BOARD APPOINTED DAVID LAZAR AS CEO OF COKALA BIO-  BOARD APPOINTED DAVID LAZAR AS PRINCIPAL FINANCIAL OFFICER OF COMPANYSource text: [ID:n0001829126-25-009432]Further company coverage: KALA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10XX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2586708401","title":"KALA BIO Raises $1.8M in Preferred Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2586708401","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586708401?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:51","pubTimestamp":1764107468,"startTime":"0","endTime":"0","summary":"KALA BIO ( ($KALA) ) has issued an update. On November 23, 2025, KALA BIO entered into a Securities Purchase Agreement to issue Series AA and Serie...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kala-bio-raises-1-8m-in-preferred-stock-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kala-bio-raises-1-8m-in-preferred-stock-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4153","BK4007","BK4585","BIO","KALA","BK4121","LU1169589451.USD","AA","BK4139","LU1169590202.USD"],"gpt_icon":0},{"id":"2586440924","title":"KALA BIO Inc - on Nov 21, Board Terminated Without Cause the Employment of Mary Reumuth, Company's Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586440924","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586440924?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:23","pubTimestamp":1764105833,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10XX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2586409791","title":"KALA BIO Inc - on Nov 21, Board Appointed David Lazar as CEO of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2586409791","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586409791?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:23","pubTimestamp":1764105833,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X10XX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","KALA"],"gpt_icon":0},{"id":"2586140916","title":"Kala Bio Inc. Announces $6 Million Private Placement of Preferred Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586140916","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586140916?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:16","pubTimestamp":1764105404,"startTime":"0","endTime":"0","summary":"Kala Bio Inc. has entered into a Securities Purchase Agreement for a private placement of preferred stock in two closings, with aggregate gross proceeds of up to $6.0 million. In the first closing, which occurred on November 24, 2025, the company issued 900,000 Series AA Preferred Shares at $2.00 per share, raising $1.8 million. The second closing will involve the issuance of 2,100,000 Series AAA Preferred Shares at $2.00 per share, for additional gross proceeds of $4.2 million. The second closing is expected to take place following stockholder approval of an increase in authorized shares of common stock and the conversion of the preferred shares, among other customary closing conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL909zrt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","KALA","BK4139"],"gpt_icon":0},{"id":"2584940759","title":"Kala Bio Q3 EPS $(1.07) Beats $(1.45) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2584940759","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584940759?lang=en_us&edition=fundamental","pubTime":"2025-11-19 23:16","pubTimestamp":1763565414,"startTime":"0","endTime":"0","summary":"Kala Bio (NASDAQ:KALA) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.45) by 25.95 percent. This is a 44.56 percent increase over losses of $(1.93) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48951283/kala-bio-q3-eps-1-07-beats-1-45-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQQ","QID","BK4007","TSYW.SI","SQQQ",".IXIC","PSQ","USAW.SI","KALA","QLD","NQmain","BK4139","MNQmain","NVIW.SI","USJW.SI"],"gpt_icon":0},{"id":"2583682607","title":"Top News Today: Stocks Mixed as AI Selloff Slows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682607?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:45","pubTimestamp":1763156700,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields rose amid doubts about the Federal Reserve's next move.COMMODITIES: Oil futures rose after Ukraine drone attacks on a Russian Black Sea port.Walmart picked one of its longtime executives, John Furner, to become its next chief executive, preserving its tradition of promoting an insider to steer the nation's biggest retailer. The 51-year-old Furner was seen inside the company as the likely heir apparent and ready for his next step after six years leading Walmart's U.S. business. Outside the company, the Walmart veteran-and son of a Walmart executive-was seen as a potential CEO candidate for other firms too.The reopened federal government will on Thursday release the first backlogged monthly jobs report, for the month of September. And a flood of other data is due to start flowing soon.They promised investments in the U.S. that would reduce Switzerland's trade imbalance with the U.S., according to people familiar wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","SRG","LFMD","AAME","BK4007","LU0861579265.USD","STI","HP","TORM","WMT","XP","PRPO","IE00B2B36J28.USD","LU0061474960.USD","LU2750360641.GBP","LU2361044865.SGD","BK4211","JJSF","LU2468319806.SGD","UAVS","ASPI","BK4561","NWBO","LU2430703178.SGD","ELDN","LU2023250843.SGD","LWLG","SPRB","PNBK","LU0203347892.USD","BYFC","LU2430703251.USD","ARMK","RHEP","LU1430594728.SGD","LU2592432038.USD","LU1974910355.USD","IPAR","KALA","TVGN","IIIV","LITS","MRK","BRC","GPUS","ALBT","ALTS","BK4152","OTLC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kalarx.com","stockEarnings":[{"period":"1week","weight":-0.0323},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.9653},{"period":"6month","weight":-0.8752},{"period":"1year","weight":-0.9009},{"period":"ytd","weight":-0.9155}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.021157},{"month":2,"riseRate":0.25,"avgChangeRate":-0.068238},{"month":3,"riseRate":0.625,"avgChangeRate":0.271513},{"month":4,"riseRate":0.375,"avgChangeRate":-0.095725},{"month":5,"riseRate":0.25,"avgChangeRate":-0.117576},{"month":6,"riseRate":0.5,"avgChangeRate":0.007868},{"month":7,"riseRate":0.375,"avgChangeRate":-0.025178},{"month":8,"riseRate":0.444444,"avgChangeRate":0.043537},{"month":9,"riseRate":0,"avgChangeRate":-0.257871},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.21893},{"month":11,"riseRate":0.555556,"avgChangeRate":0.039437},{"month":12,"riseRate":0.333333,"avgChangeRate":0.573363}],"exchange":"NASDAQ","name":"KALA BIO","nameEN":"KALA BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"KALA BIO(KALA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest KALA BIO(KALA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"KALA BIO,KALA,KALA BIO股票,KALA BIO股票老虎,KALA BIO股票老虎国际,KALA BIO行情,KALA BIO股票行情,KALA BIO股价,KALA BIO股市,KALA BIO股票价格,KALA BIO股票交易,KALA BIO股票购买,KALA BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"KALA BIO(KALA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest KALA BIO(KALA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction